Payment overview · 2025
General Payments
$384.04
21 reported records · 13 companies
Healthcare provider profile · identity verified
Jaya Thakur, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHILLICOTHE, OH · NPI 1457589277
Verified facts
What the public records show
CMS Open Payments records show Jaya Thakur, MD received $384.04 in general payments during 2025 across 21 reported records.
Lilly USA, LLC accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.57 | 20.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.06 | 14.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.66 | 12.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.19 | 8.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.80 | 7.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.37 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.02 | 5.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.36 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.08 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.75 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.60 | 4.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.59 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.99 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.04 | 20 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 171 |
| Omeprazole | Omeprazole | 576 | 131 |
| Lisinopril | Lisinopril | 501 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 496 | 110 |
| Gabapentin | Gabapentin | 427 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 346 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 94 |
| Losartan Potassium | Losartan Potassium | 324 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 83 |
| Simvastatin | Simvastatin | 299 | 58 |
| Metformin Hcl | Metformin Hcl | 283 | 77 |
| Famotidine | Famotidine | 274 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 87 |
| Furosemide | Furosemide | 257 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 42 |
| Potassium Chloride | Potassium Chloride | 184 | 41 |
| Alendronate Sodium | Alendronate Sodium | 178 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 46 |
| Metformin Hcl Er | Metformin Hcl | 168 | 34 |
| Ozempic | Semaglutide | 166 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 165 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 35 |
| Sertraline Hcl | Sertraline Hcl | 142 | 31 |
| Atenolol | Atenolol | 141 | 35 |
| Tramadol Hcl | Tramadol Hcl | 141 | 22 |
| Trazodone Hcl | Trazodone Hcl | 140 | 20 |
| Clonazepam | Clonazepam | 138 | 17 |
| Alprazolam | Alprazolam | 129 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 127 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 15 |
| Allopurinol | Allopurinol | 104 | 28 |
| Lorazepam | Lorazepam | 104 | 17 |
| Eliquis | Apixaban | 99 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 21 |
| Montelukast Sodium | Montelukast Sodium | 94 | 21 |
| Glimepiride | Glimepiride | 93 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 11 |
| Bupropion Xl | Bupropion Hcl | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 20 |
| Meloxicam | Meloxicam | 78 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 26 |
| Carvedilol | Carvedilol | 73 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 21 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 14 |
| Methylprednisolone | Methylprednisolone | 69 | 53 |
| Nystatin | Nystatin | 68 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 26 |
| Xarelto | Rivaroxaban | 68 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 51 |
| Jardiance | Empagliflozin | 67 | 19 |
| Azithromycin | Azithromycin | 66 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 13 |
| Diazepam | Diazepam | 65 | 11 |
| Mupirocin | Mupirocin | 65 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Lovastatin | Lovastatin | 62 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 58 | 14 |
| Ondansetron Odt | Ondansetron | 58 | 21 |
| Ibuprofen | Ibuprofen | 57 | 14 |
| Januvia | Sitagliptin Phosphate | 57 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 36 |
| Topiramate | Topiramate | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 28 |
| Cephalexin | Cephalexin | 48 | 44 |
| Fluconazole | Fluconazole | 47 | 30 |
| Cefdinir | Cefdinir | 46 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Spironolactone | Spironolactone | 45 | 13 |
| Sucralfate | Sucralfate | 45 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Promethazine Hcl | Promethazine Hcl | 42 | 11 |
| Hydrocortisone | Hydrocortisone | 40 | 23 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 35 |
| Glipizide | Glipizide | 38 | 13 |
| Lidocaine | Lidocaine | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 20 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Prednisone | Prednisone | 35 | 26 |
| Linzess | Linaclotide | 34 | suppressed |
| Clotrimazole | Clotrimazole | 33 | 20 |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ofloxacin | Ofloxacin | 24 | 20 |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | 13 |
| Finasteride | Finasteride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Torsemide | Torsemide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $384.04 · 21 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, SHINGRIX, VERQUVO, VOQUEZNA, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error